N-lysine methyltransferase KMT5A serves a crucial role in the progression of human cancer; however, the function of KMT5A in the development of ccRCCs has not yet been investigated, which has triggered an interest in investigating the potential association between KMT5A and ccRCC.
Mounting evidence suggested that histone H4K20-specific methyltransferase SET8 is required to maintain the malignant phenotype of various cancer types; however, the role of SET8 in mediating tumor metastasis in prostate cancer (PCa) has remained elusive.
Thus, the miR-502/SET8 regulatory circuit emerges as a key regulator of the pathobiology of cancer and a focal point for possible therapeutic intervention.
Individuals with combined SET8 CC and TP53 GG genotypes developed cancer at a median age of 47.7 years as compared with 54.6 years for individuals with combined SET8 TT and TP53 CC genotypes.